Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 6/20 | 0.36 |
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.35 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10193069 | 0.83 | HDAC6 (0.46) | HDAC6LOXL2RAB9ANPC1GAA | |
| SCHEMBL489036 | 0.80 | TRPV1 (0.48) | HDAC6LOXL2HSD17B10RAB9ANPC1 | |
| SCHEMBL3919004 | 0.75 | UBE2T (0.61) | HSD17B10RAB9ANPC1GAAMAPK1 | |
| SCHEMBL489018 | 0.70 | RAB9A (0.47) | HDAC6RAB9ANPC1GAAHTT | |
| SCHEMBL10254309 | 0.69 | ALDH1A1 (0.57) | HSD17B10RAB9ANPC1GAAHTT | |
| SCHEMBL13539291 | 0.69 | PIK3CA (0.54) | HSD17B10RAB9ANPC1GAAHTT | |
| SCHEMBL13986778 | 0.66 | TRPV1 (0.55) | HDAC6LOXL2HSD17B10RAB9ANPC1 | |
| SCHEMBL14327114 | 0.66 | SMN1; SMN2 (0.65) | HSD17B10GAAALOX15SMN1; SMN2HPGD | |
| SCHEMBL21104587 | 0.66 | LOXL2 (0.70) | HDAC6LOXL2GAASMN1; SMN2TRPV1 | |
| SCHEMBL14835424 | 0.66 | SMN1; SMN2 (0.67) | HSD17B10RAB9ANPC1GAAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8106088-B2 | Fused bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-01-31 | — | — | US | disclosed |
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298291-A1 | FUSED BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | HDAC6 1276/4885LOXL2 1889/4885HSD17B10 3246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.